Testing a new intravenous treatment for chronic obstructive pulmonary disease

Plain-English translation of NCT07292714 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a Phase II clinical trial testing a new intravenous medication called to see if it can help people with moderate-to-severe COPD (a chronic lung disease that makes it hard to breathe). The study will compare this medication against a placebo (an inactive treatment) to measure how well the treatment works and whether it is safe. Researchers are enrolling 360 patients across multiple hospitals to evaluate whether this treatment could reduce flare-ups and improve breathing in people with COPD.

COPD patients who experience frequent, severe flare-ups have limited treatment options and face serious complications. This medication is being tested to see if it can reduce how often these flare-ups happen and help patients breathe better.

Do you qualify?

You likely qualify if…

you are between 40 and 75 years old
you have been diagnosed with COPD for at least one year
you have had at least two moderate flare-ups or one severe flare-up in the past 12 months
your lung function shows moderate-to-severe airflow obstruction (confirmed by breathing tests)
you have been a current or former smoker with at least a 10 pack-year history
you have been on stable COPD maintenance medications for at least one month

You likely don't qualify if…

you have been diagnosed with asthma or have a documented history of asthma
you have other serious lung diseases besides COPD, such as cystic fibrosis, bronchiectasis, or severe pulmonary hypertension
you require long-term oxygen therapy (more than 15 hours per day) or mechanical ventilation support
you have had a recent severe COPD flare-up, serious infection requiring hospitalization, or high-dose steroid treatment in the past four weeks
you have had a recent heart attack, stroke, or unstable heart condition within the past 6–12 months

What participation looks like

If you qualify and join this study, you will be randomly assigned to receive either the new medication or a placebo, both given as intravenous infusions. You will visit the study site multiple times for breathing tests, blood work, and check-ups to monitor how you respond to the treatment. Neither you nor your doctor will know which treatment you're receiving (this is called 'blinded'), which helps ensure fair and unbiased results. The study will track your COPD symptoms and any flare-ups over the course of the trial.

AI-generated summary from trial data · Jun 11, 2026 · Not medical advice

Trial locations(51 sites)

China

Chizhou Central Hospital, Chizhou, Anhui

Anhui Chest Hospital, Hefei, Anhui

Gansu Provincial People's Hospital, Lanzhou, Gansu

Huizhou Third People's Hospital, Huizhou, Guangdong

Jiangmen Central Hospital, Jiangmen, Guangdong